PANACEABIO2023-04-012023-06-30 PANACEABIO2023-04-012023-06-30in-bse-fin:OneOperatingExpenses01Member PANACEABIO2023-06-30 PANACEABIO2023-04-012023-06-30in-bse-fin:OneReportableSegmentRevenue01Member PANACEABIO2023-04-012023-06-30in-bse-fin:OneReportableSegmentRevenue02Member PANACEABIO2023-04-012023-06-30in-bse-fin:OneReportableSegmentResults01Member PANACEABIO2023-04-012023-06-30in-bse-fin:OneReportableSegmentResults02Member PANACEABIO2023-04-012023-06-30in-bse-fin:OneReportableSegmentAssets01Member PANACEABIO2023-04-012023-06-30in-bse-fin:OneReportableSegmentAssets02Member PANACEABIO2023-04-012023-06-30in-bse-fin:OneReportableSegmentLiabilities01Member PANACEABIO2023-06-30in-bse-fin:OneReportableSegmentLiabilities01Member PANACEABIO2023-04-012023-06-30in-bse-fin:OneReportableSegmentLiabilities02Member PANACEABIO2023-06-30in-bse-fin:OneReportableSegmentLiabilities02Member PANACEABIO2023-04-012023-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member PANACEABIO2023-04-012023-06-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 531349 PANACEABIO NOTLISTED Panacea Biotec Limited Equity 2023-04-01 2024-03-31 2023-08-12 2023-07-29 INR Lakhs First quarter 11:30:00 15:00:00 2023-08-12 2023-08-12 Not applicable Multi segment 2023-04-01 2023-06-30 Unaudited Consolidated 1291900000.00 60800000.00 1352700000.00 573200000.00 12000000.00 -36600000.00 359700000.00 10000000.00 94800000.00 486700000.00 1499800000.00 -147100000.00 277400000.00 130300000.00 0.00 20500000.00 20500000.00 0.00 109800000.00 0.00 0.00 0.00 0.00 109800000.00 1000000.00 110800000.00 110100000.00 700000.00 61300000.00 1 1.79 1.79 0.00 0.00 1.79 1.79 Notes: 1. The above financial results of Panacea Biotec Limited (‘the Company’ or ‘PBL’) were reviewed by the Audit Committee of the Board of Directors and approved by the Board of Directors at their meetings held on August 11, 2023 and August 12, 2023 respectively and have been reviewed by the statutory auditors of the Company. 2. The financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (“IND AS”) notified under the Companies (Indian Accounting Standards) Rule, 2015, as amended from time to time, specified under section 133 of the Companies Act, 2013. 3. The unaudited consolidated financial results of the Company have been prepared by consolidating the Company's financial results for the respective periods with the unaudited financial results of the following wholly-owned subsidiaries (“WOS”) and the Enterprises over which the Company exercises control (collectively, the Company, these subsidiaries and the enterprises hereinafter referred to as “the Group”): (i) Indian WOS: Panacea Biotec Pharma Limited (“PBPL”) and Meyten Realtech Private Limited; (ii) Overseas WOS: Panacea Biotec (International) S.A., and Panacea Biotec Germany GmbH; and (iii) Enterprises over which the Company exercises control: PanEra Biotec Private Limited and Adveta Power Private Limited. 4. For the quarter ended June 30, 2023, the Company has earned profit (before tax and exceptional items) of Rs.129 lakh (year ended March 31, 2023: loss of Rs.6,275 lakh) and the Group has incurred a loss (before tax and exceptional items) of Rs.1,471 lakh (year ended March 31, 2023: loss of Rs. 8,986 lakh). In March, 2022, PBPL had sold its Pharmaceutical Formulations Brands in India and Nepal, as explained in Note 5 below, for consideration of Rs.187,200 lakh, which enabled the Group to repay its outstanding dues of Non-Convertible Debenture (NCDs) and retain sufficient surplus to fund its existing projects and operations and also help the Group to enter new market and expediting development of new products. The surplus funds with the Group has also strengthened the working capital position and scaling up its pharmaceutical formulations business in international markets including ROW countries, USA / EU, etc. and to pursue other business opportunities. The Company has already received higher long-term business orders for vaccines from key institutional customers. Based on these measures and continuous efforts to improve the business performance, the management has prepared the financial results on going concern basis. Other Expenses 486700000.00 Formulations 397800000.00 Vaccines 894100000.00 1291900000.00 0.00 1291900000.00 Formulations 99600000.00 Vaccines 30700000.00 130300000.00 0.00 0.00 5. During the quarter ended June 30, 2023, the Group has recognised revenue of Rs.2,774 lakh, out of the remaining deferred consideration of Rs.9,313 lakh from sale of domestic pharmaceutical brands, under “Exceptional Item” in the statement of the profit and loss and the balance deferred consideration of Rs.6,539 lakh would be recognised as revenue in subsequent quarters / years and is shown as Contract Liability. 6. During the quarter, the Company’s wholly owned subsidiary company Panacea Biotec Pharma Limited has launched its new range of high-quality pediatric food & nutritional brand portfolio comprising of ChilRun, ChilRun Full, ChilRun No Sucrose and ChilRun 7+ brand in different flavours and sizes in India. 7. The Company publishes standalone financial results along with the consolidated financial results. In accordance with Ind AS 108, ‘Operating Segments’, the management has disclosed the segment information in the unaudited consolidated financial results. Accordingly, the segment information is given in the unaudited consolidated financial results of the Group for the quarter ended June 30, 2023. 8. The necessary certificate / report in respect of the above results in terms of requirement of Regulation 33 of the SEBI (Listing Obligations and Other Disclosure Requirements) Regulations, 2015, has been placed before the Board of Directors. 9. Previous period amounts have been regrouped/ reclassified in compliance with IND-AS to make them comparable with those of current period/ year. 10. ‘0’ under “Rs. in Lakh” represents amount less than Rs.50,000. Further, the figures shown in the tables may not exactly add up due to rounding off. 11. The above results are also available on the Company’s website https://www.panaceabiotec.com 130300000.00 Formulations 4781600000.00 Vaccines 8156200000.00 12937800000.00 0.00 12937800000.00 Formulations 1224600000.00 Vaccines 3226000000.00 4450600000.00 0.00 4450600000.00 Items that will not be reclassified to profit or loss 1300000.00 1300000.00 300000.00 Items that will be reclassified to profit or loss 0.00 0.00 0.00